Skip to main content
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1996 Dec;106(3):462–467. doi: 10.1046/j.1365-2249.1996.d01-868.x

RANTES in onchocerciasis: changes with ivermectin treatment

P J COOPER *, R H GUDERIAN *, D PRAKASH , D G REMICK , I ESPINEL *, T B NUTMAN , D W TAYLOR §, G E GRIFFIN *
PMCID: PMC2200626  PMID: 8973613

Abstract

Adverse reactions are seen relatively frequently after treatment of onchocerciasis patients with ivermectin. The chemokines RANTES and IL-8, which have both chemotactic and activation properties for eosinophils and neutrophils, respectively, may have a role in the pathogenesis of post-treatment reactions. Circulating levels of the chemokines and the cytokines tumour necrosis factor-alpha (TNF-α) and IL-6 were measured in the plasma of 22 Onchocerca volvulus-infected subjects. Peaks of mean circulating levels of RANTES and TNF-α were seen at 6 h after ivermectin administration. Peripheral eosinophil counts declined at 36 h post-treatment and an early peak in RANTES levels was associated with a delay in peripheral eosinopenia. RANTES levels were negatively correlated with severity of rash (P < 0.001) and lymphoedema (P < 0.05), suggesting that high circulating levels of RANTES may inhibit eosinophil sequestration. No changes in circulating levels of IL-8 were seen. These findings suggest a possible role of circulating RANTES in modulating eosinophil sequestration in vivo.

Keywords: onchocerciasis, ivermectin, chemokines, RANTES, cytokines

Full Text

The Full Text of this article is available as a PDF (263.7 KB).


Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES